Approach to Peripheral Neuropathy

Initial Diagnostic Evaluation

The American Academy of Neurology recommends characterizing pain using a 0-10 numerical rating scale, as baseline pain ≥4 is clinically significant and guides treatment decisions 1, 2
Documenting medication history, including chemotherapeutic agents, is crucial as dose adjustment may be the primary intervention 3, 4
Assessing functional impact on walking, balance, and activities of daily living is essential 1

The American College of Physicians recommends ordering a focused initial panel, including complete blood count, comprehensive metabolic profile, fasting glucose, hemoglobin A1c, vitamin B12, thyroid-stimulating hormone, and serum protein electrophoresis with immunofixation 2

The American Diabetes Association recommends optimizing glycemic control immediately with a target HbA1c of 6-7% to prevent progression of diabetic peripheral neuropathy 3, 2, 4
Addressing cardiovascular risk factors aggressively, such as controlling hypertension and hyperlipidemia, contributes to preventing neuropathy progression 3, 2

The American Academy of Neurology recommends starting duloxetine 60 mg once daily as first-line treatment for painful diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy 3, 2, 4
Pregabalin 150 mg/day divided twice daily, titrated to 300-600 mg/day over 1 week, is a first-line option with an NNT of 4.04-5.99 3, 4
Gabapentin 300 mg at bedtime, titrated to 900-3600 mg/day divided three times daily over 1-2 weeks, is a first-line option with similar efficacy to pregabalin 3, 4

The American College of Sports Medicine recommends regular exercise and functional training to reduce neuropathic symptoms 4
Wearing loose-fitting shoes and cotton socks is advised to reduce pressure on affected areas 3

Reassessing pain scores and quality of life at each visit using the same 0-10 scale is crucial 1, 3
Screening diabetic patients annually for progression of neuropathy and development of foot ulcers is essential 2

The American Diabetes Association recommends tricyclic antidepressants (amitriptyline 25-75 mg/day or imipramine 25-75 mg/day) as effective first-line agents for neuropathic pain, with significant anticholinergic side effects 5, 6
Tricyclic antidepressants inhibit noradrenaline and serotonin reuptake in central descending pain-control systems, providing pain relief 5

The American Academy of Neurology suggests considering sodium channel blockers (carbamazepine 200-800 mg/day, lamotrigine) when first-line agents fail, with moderate evidence supporting their use 5
Spinal cord stimulation may be considered for extreme cases unresponsive to pharmacotherapy, with limited evidence supporting its use 5, 6